NCT04696315Completed
Early Diagnosis of SCD Based on Radiogenomics
Comparison of Subjective Cognitive Decline Between the German and Chinese and Early Diagnosis of Alzheimer's Disease Based on Radiogenomics
Source: ClinicalTrials.gov · Last updated 21 Aug 2026
Brief summary (registry, in English)
The incidence of AD dementia is increasing due to the aging population, putting a heavy burden on our society and economics. Exploring the mechanisms underlying SCD due to preclinical AD has scientific and clinical significance. However, it is challenging to construct and validate the preclinical diagnosis model of AD with fused multimodel information across culture/race. From the cooperation during the past five years, we have established cohorts by synchronized assessment, achieved consensus on SCD features extraction and made a breakthrough in the application of multiple parameter MRI with German collaborators. Therefore, in this project, SCD with and without amyloid pathology will be compared by clinical and cognitive data, genetics, blood and MRI biomarkers between the German and Chinese. Key features will be extracted and specific characteristics of SCD due to preclinical AD as well as risk factors for conversion between two countries will be clarified. Then the diagnosis model of preclinical AD in SCD will be established across culture/race based on radiogenomics, which will improve the current diagnostic system of AD. Through this project, the value of SCD in the etiologic, anatomical and quantitative diagnosis of preclinical AD will be identified to improve sensitivity and specificity of preclinical AD diagnosis in clinical practice.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 800 (actual)
- First submitted
- 3 Jan 2021
- Start date
- 1 Jan 2021
- Primary completion date
- 31 Dec 2024
- Lead sponsor
- Ying Han
- Diseases
- Alzheimer disease
- NCT number
- NCT04696315
What you commit to
- Study type: Observational
- Participants enrolled: 800
- From 1 Jan 2021 to the primary completion date, 31 Dec 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- a history of stroke;
- other central nervous system diseases that may cause cognitive impairment, such as Parkinson's disease, tumors, encephalitis and epilepsy;
- cognitive impairment caused by traumatic brain injury;
- systemic diseases, such as thyroid dysfunction, syphilis and HIV;
- a history of psychosis or congenital mental growth retardation
Other
- major depression (Hamilton Depression Rating Scale score \> 24 points);
Who the study is looking for
- 60-79 years old, right-handed and Mandarin-speaking subjects;
- self-experienced persistent decline in cognitive capacity in comparison with a previously normal status and unrelated to an acute event;
- normal age-, gender- and education-adjusted performance on standardised cognitive tests;
- concerns (worries) associated with memory complaint;
- failure to meet the criteria for MCI or dementia
Age in the registry: 60 years to 79 years · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Neurolgy, Xuanwu Hospital of Capital Medical University Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.